Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 10/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25459484 | 0.79 | ADORA3 (0.48) | ADORA3CNR1 | |
| SCHEMBL28895089 | 0.78 | KMT2A (0.48) | KDM4EMEN1NPC1MAPTKMT2A | |
| SCHEMBL28895091 | 0.78 | KMT2A (0.48) | KDM4EMEN1NPC1MAPTKMT2A | |
| SCHEMBL30085581 | 0.78 | KMT2A (0.48) | KDM4EMEN1NPC1MAPTKMT2A | |
| SCHEMBL30085837 | 0.74 | FGFR3 (0.48) | NPC1ADORA3CNR1 | |
| SCHEMBL25458392 | 0.74 | FGFR3 (0.48) | NPC1ADORA3CNR1 | |
| SCHEMBL25458389 | 0.73 | KDR (0.50) | MEN1NPC1MAPTKMT2AADORA3 | |
| SCHEMBL30085870 | 0.73 | KDR (0.50) | MEN1NPC1MAPTKMT2AADORA3 | |
| SCHEMBL30085442 | 0.72 | LRRK2 (0.48) | IRAK1KDM4EIRAK4 | |
| SCHEMBL28894975 | 0.72 | LRRK2 (0.48) | IRAK1KDM4EIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | IRAK1 562/4885KDM4E 1188/4885MEN1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.